We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
VYNDAQEL (Pfizer Australia Pty Ltd)
Product name
VYNDAQEL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
187 working days (255)
Active ingredients
tafamidis meglumine
Registration type
NCE/NBE
Indication
VYNDAQEL (soft capsules) is indicated for the treatment of adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.